Vawter Financial Ltd. purchased a new stake in Stryker Corporation (NYSE:SYK – Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 1,972 shares of the medical technology company’s stock, valued at approximately $729,000.
Other institutional investors have also made changes to their positions in the company. Clayton Financial Group LLC bought a new position in Stryker in the 3rd quarter worth approximately $26,000. Elevation Point Wealth Partners LLC acquired a new stake in shares of Stryker in the second quarter worth $28,000. Kilter Group LLC bought a new position in Stryker during the second quarter worth $29,000. Howard Hughes Medical Institute acquired a new position in Stryker during the 2nd quarter valued at $29,000. Finally, ANTIPODES PARTNERS Ltd bought a new stake in Stryker in the 3rd quarter valued at $34,000. 77.09% of the stock is currently owned by institutional investors.
Stryker Price Performance
Stryker stock opened at $381.84 on Wednesday. The business has a 50 day simple moving average of $361.24 and a 200 day simple moving average of $368.91. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.89 and a quick ratio of 1.21. The company has a market capitalization of $146.13 billion, a PE ratio of 45.46, a price-to-earnings-growth ratio of 2.25 and a beta of 0.87. Stryker Corporation has a one year low of $329.16 and a one year high of $404.87.
Stryker Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be given a $0.88 dividend. The ex-dividend date is Tuesday, March 31st. This represents a $3.52 dividend on an annualized basis and a yield of 0.9%. Stryker’s payout ratio is 41.90%.
Analysts Set New Price Targets
A number of research analysts have recently commented on SYK shares. BTIG Research upped their price objective on shares of Stryker from $410.00 to $412.00 and gave the company a “buy” rating in a research report on Friday, January 30th. Wall Street Zen upgraded Stryker from a “hold” rating to a “buy” rating in a research report on Saturday. Sanford C. Bernstein lifted their price objective on Stryker from $450.00 to $465.00 and gave the stock an “outperform” rating in a report on Friday, January 9th. UBS Group upped their target price on Stryker from $386.00 to $400.00 and gave the company a “neutral” rating in a research note on Tuesday. Finally, Wells Fargo & Company raised their target price on Stryker from $452.00 to $456.00 and gave the stock an “overweight” rating in a research report on Friday, November 14th. Thirteen analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $426.47.
Check Out Our Latest Research Report on SYK
Insider Buying and Selling
In other news, Director Ronda E. Stryker sold 250,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the completion of the sale, the director owned 2,457,331 shares of the company’s stock, valued at approximately $891,814,566.52. This trade represents a 9.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 5.20% of the stock is currently owned by company insiders.
Stryker Profile
Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.
Featured Articles
- Five stocks we like better than Stryker
- The gold chart Wall Street is terrified of…
- America’s 1776 happening again
- Buy this Gold Stock Before May 2026
- This makes me furious
- What a Former CIA Agent Knows About the Coming Collapse
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYK – Free Report).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
